Here’s how Trump might approach his drug pricing plan

What's new in pharma

May 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Moneymaker/Getty Images STAT+ | Here's how Trump might approach his drug pricing plan The idea, known in Washington as a most-favored nation policy, was shot down in the past by pharma lobby and Republicans opposed to drug price controls. By John Wilkerson and Daniel Payne STAT+ | 5 burning questions about FDA's 'aggressive' deployment of AI for scientific review FDA's plan to rapidly deploy a generative AI tool to assist with its scientific review process raises questions about transparency and risks By Katie Palmer and Casey Ross STAT+ | Medicare Advantage challenges catch up to UnitedHealth Insurer's stock price battered after slashed profit forecast, as risk adjustment changes known as V28 hit UnitedHealth. By Bob Herman Adobe STAT+ | From pandemic preparedness to precious frozen spit, NIH contract terminations cut deep NIH has ended contracts for scientists working on vaccines, cut off pandemic-preparedness projects, and slashed support for equipment repairs By Megan Molteni and Jason Mast STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser